GlassScriptPhysician profile
John L Washington
NPI 1376885996
$6,963.97
in general payments reported to CMS, 2019-2025
34 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $898 · 2023: $1,424 · 2024: $2,005 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,458 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,457.76 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,136.29 | 2021-2025 | |
| Janssen Biotech, INC. | $1,176.65 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $597.04 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $417.27 | 2021-2025 | |
| Gilead Sciences, INC. | $296.59 | 2022-2025 | Livdelzi |
| Genzyme Corporation | $274.86 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $263.56 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $216.46 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.61 | 2022-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $158.76 | 2024 | |
| Lilly USA, LLC | $136.32 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $131.59 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $127.41 | 2021-2025 | Ocaliva |
| Fresenius Kabi USA, LLC | $90.11 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Merck Sharp & Dohme LLC | $89.10 | 2022-2023 | Zinplava, Dificid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $80.20 | 2021-2022 | |
| Celgene Corporation | $73.80 | 2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $66.30 | 2024 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $63.63 | 2022-2024 | Linzess |
| Daiichi Sankyo INC. | $57.73 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $41.14 | 2023 | Andexxa |
| Axonics, INC. | $39.98 | 2024 | Axonics |
| Braintree Laboratories, INC. | $33.67 | 2022-2023 | Sutab |
| Amgen INC. | $28.89 | 2023 | Avsola |
| Madrigal Pharmaceuticals | $24.67 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.89 | 2023 | Cyltezo |
| Tersera Therapeutics LLC | $21.34 | 2022 | |
| Novo Nordisk INC | $20.52 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $19.38 | 2022 | |
| Medtronic, INC. | $19.01 | 2023 | Signia |
| Vivus LLC | $17.70 | 2024 | Pancreaze |
| Lucid Diagnostics INC. | $17.32 | 2024 | |
| Amag Pharmaceuticals, INC. | $17.11 | 2021 | |
| Nestle Healthcare Nutrition INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Washington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.